Key statistics
As of last trade, aTyr Pharma Inc (471A:FRA) traded at 1.56, 58.38% above the 52 week low of 0.985 set on Nov 15, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.56 |
---|---|
High | 1.56 |
Low | 1.56 |
Bid | 1.55 |
Offer | 1.63 |
Previous close | 1.64 |
Average volume | 561.11 |
---|---|
Shares outstanding | 75.80m |
Free float | 73.98m |
P/E (TTM) | -- |
Market cap | 134.16m USD |
EPS (TTM) | -0.9047 USD |
Data delayed at least 15 minutes, as of Sep 24 2024 07:15 BST.
More ▼
Announcements
- aTyr Pharma to Participate in September Investor Conferences
- aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
- aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
- aTyr Pharma Announces Research Study with Stanford Medicine
- aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
- aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
- aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
- aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
- aTyr Pharma to Present at Upcoming Investor Conferences
More ▼